Pharmacological analysis and structure determination of 7-methylcyanopindolol-bound β1-adrenergic receptor

Molecular Pharmacology

Volumn 88, Issue 6, 2015, Pages 1024-1034

  Sato, Tomomi ^a,d   Baker, Jillian ^c   Warne, Tony ^a   Brown, Giles A ^b   Leslie, Andrew G W ^a   Congreve, Miles ^b   Tate, Christopher G ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b Heptares Therapeutics Ltd   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d INSTITUTE OF MATERIALS STRUCTURE SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (BENZYLOXY) 5 METHYLBENZALDEHYDE; 4 (BENZYLOXY) 7 METHYL 1H INDOLE 2 CARBOXAMIDE; 4 (BENZYLOXY) 7 METHYL 1H INDOLE 2 CARBOXYLIC ACID; 4 HYDROXY 7 METHYL -1H INDOLE 2 CARBOXAMIDE; 4 HYDROXY 7 METHYL 1H INDOLE 2 CARBONITRILE; 4 [3 (TERT BUTYLAMINO) 2 HYDROXYPROPOXY] 7 METHYL 1H INDOLE 2 CARBONITRILE; 7 METHYL 4 [ OXIRAN 2 YLMETHOXY] 1H INDOLE 2 CARBONITRILE; 7 METHYLCYANOPINDOLOL; BETA 1 ADRENERGIC RECEPTOR; CYANOPINDOLOL; HYDROXYL GROUP; METHYL 4 (BENZYLOXY) 7 METHYL 1H INDOLE 2 CARBOXYLATE; METHYL GROUP; PARTIAL AGONIST; UNCLASSIFIED DRUG; PINDOLOL; PROTEIN BINDING;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHO CELL LINE; CRYSTALLIZATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC TRANSCRIPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTON NUCLEAR MAGNETIC RESONANCE; ANALOGS AND DERIVATIVES; ANIMAL; BINDING SITE; CHEMISTRY; CRICETULUS; HAMSTER; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION; TURKEY;

ANIMALS; BINDING SITES; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; PINDOLOL; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, ADRENERGIC, BETA-1; STRUCTURE-ACTIVITY RELATIONSHIP; TURKEY;

EID: 84948697725     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.101030     Document Type: Article

References (38)

1. Azzi M, Piñeyro G, Pontier S, Parent S, Ansanay H, and Bouvier M (2001) Allosteric effects of G protein overexpression on the binding of beta-adrenergic ligands with distinct inverse efficacies. Mol Pharmacol 60:999-1007.
2. Baker JG (2010a) A full pharmacological analysis of the three Turkey β-adrenoceptors and comparison with the human β-adrenoceptors. PLoS One 5:e15487.
3. Baker JG (2010b) The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol 160:1048-1061.
4. Baker JG, Hall IP, and Hill SJ (2003) Agonist and inverse agonist actions of betablockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
5. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors. Methods Neurosci 25:366-428.
6. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, and Allen LF et al. (1995) Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature 374:272-276.
7. Chen VB, Arendall WB, 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, and Richardson DC (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66:12-21.
8. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, and Kobilka BK et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265.
9. Christopher JA, Brown J, Doré AS, Errey JC, Koglin M, Marshall FH, Myszka DG, Rich RL, Tate CG, and Tehan B et al. (2013) Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J Med Chem 56:3446-3455.
10. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, 3rd, Snoeyink J, and Richardson JS et al. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35:W375-W383.
11. Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
12. Engelhardt S, Grimmer Y, Fan GH, and Lohse MJ (2001) Constitutive activity of the human beta(1)-adrenergic receptor in beta(1)-receptor transgenic mice. Mol Pharmacol 60:712-717.
13. Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62:72-82.
14. Evans PR (2011) An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr D Biol Crystallogr 67:282-292.
15. Lebon G, Warne T, and Tate CG (2012) Agonist-bound structures of G proteincoupled receptors. Curr Opin Struct Biol 22:482-490.
16. Leslie AG (2006) The integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 62:48-57.
17. Liapakis G, Ballesteros JA, Papachristou S, Chan WC, Chen X, and Javitch JA (2000) The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor. J Biol Chem 275:37779-37788.
18. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. J Appl Cryst 40:658-674.
19. Miller JL and Tate CG (2011) Engineering an ultra-thermostable b(1)-adrenoceptor. J Mol Biol 413:628-638.
20. Miller-Gallacher JL, Nehmé R, Warne T, Edwards PC, Schertler GF, Leslie AG, and Tate CG (2014) The 2.1 Å resolution structure of cyanopindolol-bound β1-adrenoceptor identifies an intramembrane Na1 ion that stabilises the ligandfree receptor. PLoS One 9:e92727.
21. Moukhametzianov R, Warne T, Edwards PC, Serrano-Vega MJ, Leslie AG, Tate CG, and Schertler GF (2011) Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor. Proc Natl Acad Sci USA 108:8228-8232.
22. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, and Vagin AA (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67:355-367.
23. Murshudov GN, Vagin AA, and Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255.
24. Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, and Kobilka TS et al. (2011a) Structure of a nanobodystabilized active state of the b(2) adrenoceptor. Nature 469:175-180.
25. Rasmussen SG, De Vree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, and Calinski D et al. (2011b) Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477:549-555.
26. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, and Stevens RC et al. (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318:1266-1273.
27. Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, and Sunahara RK et al. (2011) Structure and function of an irreversible agonist-b(2) adrenoceptor complex. Nature 469:236-240.
28. Roth CB, Hanson MA, and Stevens RC (2008) Stabilization of the human beta2-adrenergic receptor TM4-TM3-TM5 helix interface by mutagenesis of Glu122(3.41), a critical residue in GPCR structure. J Mol Biol 376:1305-1319.
29. Schaffner W and Weissmann C (1973) A rapid, sensitive, and specific method for the determination of protein in dilute solution. Anal Biochem 56:502-514.
30. Strader CD, Candelore MR, Hill WS, Sigal IS, and Dixon RA (1989) Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 264:13572-13578.
31. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, and Babu MM (2013) Molecular signatures of G-protein-coupled receptors. Nature 494:185-194.
32. Wacker D, Fenalti G, Brown MA, Katritch V, Abagyan R, Cherezov V, and Stevens RC (2010) Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc 132: 11443-11445.
33. Warne T, Chirnside J, and Schertler GF (2003) Expression and purification of truncated, non-glycosylated turkey beta-adrenergic receptors for crystallization. Biochim Biophys Acta 1610:133-140.
34. Warne T, Edwards PC, Leslie AG, and Tate CG (2012) Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 20:841-849.
35. Warne T, Moukhametzianov R, Baker JG, Nehmé R, Edwards PC, Leslie AG, Schertler GF, and Tate CG (2011) The structural basis for agonist and partial agonist action on a b(1)-adrenergic receptor. Nature 469:241-244.
36. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, and Schertler GF (2008) Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454:486-491.
37. Warne T, Serrano-Vega MJ, Tate CG, and Schertler GF (2009) Development and crystallization of a minimal thermostabilised G protein-coupled receptor. Protein Expr Purif 65:204-213.
38. Warne T and Tate CG (2013) The importance of interactions with helix 5 in determining the efficacy of β-adrenoceptor ligands. Biochem Soc Trans 41:159-165.